Research programme: ubiquitin-like modifier-activating enzyme 1 inhibitors - Celon Pharma
Latest Information Update: 28 Mar 2025
At a glance
- Originator Celon Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Ubiquitin protein ligase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for research development in Haematological-malignancies in Poland
- 28 Mar 2025 No recent reports of development identified for research development in Solid-tumours in Poland
- 29 Mar 2023 Research programme: ubiquitin-like modifier-activating enzyme 1 inhibitors - Celon Pharma is still in research phase for Solid tumours in Poland (unspecified route) (Celon Pharma Pipeline, March 2023)